Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
68.05+0.46 (+0.68%)
As of 3:10 AM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close67.59
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range67.91 - 68.14
52wk Range24.83 - 93.82
1y Target EstN/A
Market Cap86.54B
P/E Ratio (ttm)21.16
Avg Vol (3m)9,729
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • The Wall Street Journal2 hours ago

    [$$] Corporate-Bond Buying Attracts Doubts as Growth Tool for Europe

    European central banks are looking to corporate debt to help get the region’s economy firing on all cylinders again, but many companies are wary of investing the proceeds from those purchases.

  • Regeneron, Sanofi Skin Disease Drug Under Priority Review
    Zacks12 hours ago

    Regeneron, Sanofi Skin Disease Drug Under Priority Review

    Regeneron (REGN) and partner Sanofi's atopic dermatitis treatment, dupilumab, is under priority review in the U.S. A response should be out by Mar 29, 2017.

  • Reuters14 hours ago

    Sanofi gets $43 mln U.S. funding to spur Zika vaccine development

    Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum. The funding from the HHS' Biomedical Advanced Research and Development Authority (BARDA) will be used for mid-stage trials, expected to begin in the first half of 2018, and for manufacturing, the French drugmaker said. Work on the vaccine began in March as a collaborative effort between the U.S. Department Of Defense's Walter Reed Army Institute of Research (WRAIR), BARDA and the National Institutes of Health.